You are here

Years in the unmaking, CTI’s Pixuvri fails a pivotal PhIII combo study for lymphoma — can it remain on the market?

Years in the unmaking, CTI’s Pixuvri fails a pivotal PhIII combo study for lymphoma — can it remain on the market?

Submitted by admin on July 9, 2018 - 12:00pm

Source:

Endpoints

News Tags:

B-cell non-Hodgkin lymphoma

clinical trials

Headline:

Years in the unmaking, CTI’s Pixuvri fails a pivotal PhIII combo study for lymphoma — can it remain on the market?

snippet:

Seattle-based CTI BioPharma’s $CTIC years-long saga developing Pixuvri (pixantrone) has run into another stone wall. The company reported today that the drug, given conditional approval in Europe 6 years ago, failed a Phase III combination study in B-cell non-Hodgkin lymphoma.